Sector | Healthcare |
Industry | - |
Day Range | 16.36 | 17.10 |
52-Wk Range | - | - |
Last Close | 16.70 |
Mkt Cap (m) | 740.71 |
Dividend yield | - |
ISIN | FR0010557264 |
Volume | 270,539.00 |
Exchange Venue | PAR |
AB Science is a pharmaceutical company. It is engaged in research, development, & commercialization of tyrosine kinase inhibitors, therapeutic drugs used in treating cancerous tumors, inflammatory & neuro-degenerative diseases in both humans & animals.
Price/Earning | - |
Price/Book | 0.00 |
Price/Sales | 420.16 |
P/CF | - |
Rev Growth (3 year avg) | - |
EPS Growth (3 year avg) | - |
Operating Margin % | - |
Net Margin % | - |
Return on Equity | - |
Debt/Equity | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Revenue (m) | 2.28 | 1.51 | 1.74 | 1.70 | 1.57 | - |
Operating Income (m) | -25.96 | -30.21 | -28.40 | -28.94 | -17.47 | - |
Net Income (m) | -26.72 | -27.70 | -27.12 | -26.06 | -21.75 | - |
Basic EPS | -0.78 | -0.78 | -0.75 | -0.69 | -0.55 | - |
Avg. Diluted Shares Outstanding (m) | 34.20 | 35.65 | 35.99 | 37.78 | 39.40 | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Current Assets (m) | 30.60 | 36.12 | 48.64 | 20.71 | 14.09 | - |
Non Current Assets (m) | 1.97 | 1.89 | 1.96 | 1.78 | 3.66 | - |
Total Assets (m) | 32.58 | 38.01 | 50.60 | 22.49 | 17.74 | - |
Current Liabilities (m) | 17.61 | 20.34 | 18.71 | 19.20 | 19.53 | - |
Total Liabilities (m) | - | - | - | - | - | - |
Total Equity (m) | -17.26 | -4.71 | 10.74 | -14.96 | -26.83 | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Operating Cash Flows (m) | -23.16 | -33.52 | -22.90 | -26.79 | -15.16 | - |
Capital Expenditure (m) | -0.62 | -0.52 | -0.50 | -0.48 | -0.39 | - |